Additionally, the assays simplicity and “off-the-shelf-potential” make them very applicable for rapidly responding to emerging viral infections and costly, time-consuming high bio-containment facilities are not required as only the target viral IFN antagonist is expressed without the need for replication competent virus. This evidence concerns the gene IFNA1 and viral infectious disease.